Stephen Whitehead ABPI Chief Executive said:
“The ABPI welcomes the government’s delivery plan - ‘working to reduce the use of animals in scientific research’ endorsed across government by three departments.
The three strategic priorities identified in the plan are areas that our industry is actively pursuing. Animal research plays a small but essential role in medical, veterinary and scientific progress, and is helping us to better understand and improve the treatment of diseases in humans and animals, ultimately ensuring patients have access to innovative life-saving and life-enhancing medicines.
ABPI members are committed to the 3Rs (replacement, refinement and reduction), embedded in research and development, and our members are extensively involved in 3Rs initiatives at a UK, European and international level, some of which are undertaken in partnership with the National Centre for the Replacement, Refinement and Reduction (NC3Rs).
As a signatory to the Concordat on openness of animal research, the ABPI is also making strides to improve the transparency around animal research, which is an important ongoing priority.”
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811
Notes to editors
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.